Zimmer Wins FDA Approval for Partial Knee Implant

Zimmer Biomet announced FDA approval for its Oxford Cementless Partial Knee implant, a device that has been established in Europe since its 2004 launch, where it holds a 60% market share. Unlike traditional partial knee replacements, which rely on cement, the Oxford implant uses bone growth for fixation, demonstrating a 94.1% implant survival rate at 10 years in a U.K. registry study compared to 89.9% for other partial knee replacements. Zimmer plans to launch the implant in the U.S. in the first quarter of 2025, highlighting its potential as a major growth driver for the company’s knee portfolio in ambulatory surgical centers (ASCs), where demand for innovative, less invasive solutions is rising.

​

The FDA approval follows an investigational device exemption study validating the implant's safety and effectiveness. To ensure a successful U.S. launch, Zimmer will offer training focused on the cementless surgical technique and patient selection, emphasizing the device's benefits when used by experienced, high-caseload surgeons. CEO Ivan Tornos has positioned the Oxford device as one of Zimmer’s top growth drivers, alongside technologies like the Rosa Shoulder surgical robot and Persona IQ smart knee implant, as the company focuses on expanding its presence in the ASC market and advancing orthopedic innovation.